John serves as Vice President of Global Clinical Development, Central Nervous System, at Otsuka. In his role he responsible for the design and oversight of all clinical research programs and protocols, and he participates in due diligence of potential acquisitions, in-licensing or joint-development programs for clinical viability and the potential for commercial success. John has over 25 years of experience in clinical, academic, and pharmaceutical medicine and drug development. Most recently he was Senior Vice President, Global Head of CNS at Parexel International. Throughout his career, John has led, contributed to or managed drug development programs across several psychiatric, neurological and rare diseases, including: schizophrenia, major depressive disorder, anxiety disorders, bipolar disorder, Duchene muscular dystrophy, amyotrophic lateral sclerosis, myasthenia gravis, multiple sclerosis, epilepsy, Parkinson’s disease, Alzheimer’s disease, neuropathic pain and neuro injury. He has substantial regulatory engagement experience, including with Food and Drug Administration, Pharmaceutical and Medical Device Agency, European Medicines Agency and Paediatric Committee. John received his M.D. and Ph.D. in neurobiology from Duke University in Durham, N.C. He completed his psychiatry residency training at the University of North Carolina, Chapel Hill, N.C., where he was also chief resident. He is a Diplomate, American Board of Psychiatry & Neurology, and a Distinguished Fellow of the American Psychiatric Association.